Endocrine Abstracts

Ipilimumab, a monoclonal antibody against CTLA-4, is licenced for the treatment of metastatic melanoma (dose of 3 mg/kg for four cycles intravenously). It can cause immune-related adverse reactions (IRAEs) in multiple organs, with hypophysitis the most common endocrine IRAE. We carried out a retrospective analysis of 171 ipilimumab-treated patients in one centre for endocrinopathies.Results: Nine cases (six female, mean age 64 years, range 42–76) of...

Case history: A 53-year-old male with melanoma who had a previous surgical excision of his skin lesion in December 2018 was being treated with adjuvant pembrolizumab. In June 2019 his treatment changed to combination immune checkpoint inhibitor therapy (ICPi) with ipilimumab and nivolumab due to radiological recurrence.Investigations: There were no pre-ICPi endocrine investigations available. In July 2019, thyroid function tests (TFTs) showed thyroid-sti...

Objective: This study aimed to characterise the relationship between immune checkpoint inhibitors (ICIs), which are commonly used to treat cancer, and thyroid dysfunction in terms of the proportions affected, timing of onset, sequalae and risk factors.Design: Retrospective cohort studyMethods: Patients with normal baseline thyroid function who received an ICI were included. Proport...

Background: Immunotherapy mediated adrenocorticotrpic hormone (ACTH) deficiency is an important toxicity related to immune-checkpoint inhibitors (ICPi) potentially resulting in significant morbidity. Early diagnosis and optimal management are essential and frequently necessitate inpatient hospital treatment. We have previously reported an ambulatory management pathway for ICPi-induced ACTH deficiency in 4 patients. We sought to report the outcomes of this pathway in a larger c...